Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

220.75
+9.644.56%
Post-market: 220.750.00000.00%19:52 EDT
Volume:1.23M
Turnover:273.29M
Market Cap:11.56B
PE:-58.58
High:229.62
Open:212.71
Low:212.44
Close:211.12
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:2.63
T/O Rate:2.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:138.81
PE(LYR):-59.95

Loading ...

Axsome Therapeutics Q2 EPS USD -0.99

THOMSON REUTERS
·
Aug 10

Axsome Therapeutics Q2 Operating Expenses USD 268.021 Million

THOMSON REUTERS
·
Aug 10

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 10

Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build

Simply Wall St.
·
Aug 10

Axsome CEO Herriot Tabuteau Disposes of USD 10.54 Million in Common Shares

Reuters
·
Aug 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 07

Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?

Simply Wall St.
·
Aug 04

Earning Preview: Axsome Therapeutics revenue is expected to increase by 59.29%, and institutional views are predominantly bullish

Earnings Agent
·
Aug 03

Axsome Therapeutics is Maintained at Outperform by Mizuho

Dow Jones
·
Aug 01

Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating

MT Newswires Live
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

FDA Acceptance of AXS-12 NDA for Narcolepsy Might Change The Case For Investing In Axsome (AXSM)

Simply Wall St.
·
Jul 27

Axsome Therapeutics (AXSM) Wins FDA NDA Acceptance, Is The Stock Fully Valued?

Simply Wall St.
·
Jul 25

Axsome, Five Below, APPS, Intuit, Adobe Trending With Analysts

TIPRANKS
·
Jul 25

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

MT Newswires Live
·
Jul 21

U.S. Research Roundup-colgate-palmolive, IBM, Unitedhealth

Reuters
·
Jul 21

Axsome Therapeutics initiated with an Outperform at BMO Capital

TIPRANKS
·
Jul 21

Axsome Therapeutics Price Target Maintained with a $290.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 16

Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application

MT Newswires Live
·
Jul 15

Axsome Says FDA Accepts Axs-12 Narcolepsy Cataplexy NDA, Sets May 1, 2027 PDUFA Date

Reuters
·
Jul 15